BRPI0411221A - composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite - Google Patents
composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatiteInfo
- Publication number
- BRPI0411221A BRPI0411221A BRPI0411221-0A BRPI0411221A BRPI0411221A BR PI0411221 A BRPI0411221 A BR PI0411221A BR PI0411221 A BRPI0411221 A BR PI0411221A BR PI0411221 A BRPI0411221 A BR PI0411221A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- prevention
- disease
- methods
- inflammatory cytokines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
"COMPOSTO, MEDICAMENTO, MéTODOS PARA INIBIR A PRODUçãO DE CITOCINAS INFLAMATóRIAS, E PARA A PREVENçãO OU TRATAMENTO DE DOENçAS ASSOCIADAS COM CITOCINAS INFLAMATóRIAS, MéTODO PARA O TRATAMENTO OU ALìVIO DE FEBRE, DOR E/OU INFLAMAçãO, E, MéTODOS PARA A PREVENçãO OU TRATAMENTO DE ARTRITE REUMATóIDE, DE OSTEOARTRITE, DE DOENçA SEPTICêMICA, PSORìASE, DOENçA DE CROHN, COLITE ULCERATIVA, DIABETE MELITO OU, HEPATITE". Um composto de amina terciária cíclica que é capaz de inibir a produção de citocina inflamatória. Este é um composto que tem uma estrutura representada pela seguinte fórmula geral (I): (em que A representa um grupo trivalente opcionalmente substituído derivado de pirimidina, pirrol ou coisa parecida; R¬ 1¬ representa arila ou heteroarila opcionalmente substituidas; R¬ 2¬ representa heteroarila opcionalmente substituída; e R¬ 3¬ representa amino terciário cíclico) ou um sal farmacologicamente aceitável do composto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003165991 | 2003-06-11 | ||
PCT/JP2004/008492 WO2004111037A1 (ja) | 2003-06-11 | 2004-06-10 | 環状3級アミン化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411221A true BRPI0411221A (pt) | 2006-07-18 |
Family
ID=33549242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411221-0A BRPI0411221A (pt) | 2003-06-11 | 2004-06-10 | composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070049620A1 (pt) |
EP (1) | EP1632488A1 (pt) |
KR (1) | KR20060017865A (pt) |
CN (1) | CN1863793A (pt) |
AU (1) | AU2004247560B2 (pt) |
BR (1) | BRPI0411221A (pt) |
CA (1) | CA2528929A1 (pt) |
IL (1) | IL172338A0 (pt) |
MX (1) | MXPA05013584A (pt) |
NO (1) | NO20060142L (pt) |
RU (1) | RU2006100301A (pt) |
TW (1) | TW200508215A (pt) |
WO (1) | WO2004111037A1 (pt) |
ZA (1) | ZA200510040B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050159444A1 (en) * | 2002-07-19 | 2005-07-21 | Sankyo Company, Limited | Bicyclic unsaturated tertiary amine compounds |
ITMI20110713A1 (it) * | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
WO2008090795A1 (ja) | 2007-01-26 | 2008-07-31 | Konica Minolta Holdings, Inc. | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
KR20140045511A (ko) | 2011-07-29 | 2014-04-16 | 다이쇼 세이야꾸 가부시끼가이샤 | 아미딘 화합물 또는 그의 염 |
SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
AU2019339777B2 (en) | 2018-09-12 | 2022-09-01 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
CA3155287A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122666B2 (en) * | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
WO2001034632A2 (en) * | 1999-11-12 | 2001-05-17 | Merck & Co., Inc. | Aliphatic hydroxy substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents |
US6432980B1 (en) * | 1999-11-12 | 2002-08-13 | Merck & Co., Inc. | Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents |
ES2257336T3 (es) * | 1999-11-12 | 2006-08-01 | MERCK & CO., INC. | Derivados de diaril piperidil pirrol como agentes antiprotozoarios. |
EP1361225B1 (en) * | 2001-01-22 | 2007-11-07 | Sankyo Company, Limited | Compounds substituted with bicyclic amino groups |
US20050159444A1 (en) * | 2002-07-19 | 2005-07-21 | Sankyo Company, Limited | Bicyclic unsaturated tertiary amine compounds |
-
2004
- 2004-06-10 KR KR1020057023731A patent/KR20060017865A/ko not_active Application Discontinuation
- 2004-06-10 MX MXPA05013584A patent/MXPA05013584A/es unknown
- 2004-06-10 CN CNA2004800222942A patent/CN1863793A/zh active Pending
- 2004-06-10 BR BRPI0411221-0A patent/BRPI0411221A/pt not_active IP Right Cessation
- 2004-06-10 EP EP04746020A patent/EP1632488A1/en not_active Withdrawn
- 2004-06-10 AU AU2004247560A patent/AU2004247560B2/en not_active Ceased
- 2004-06-10 WO PCT/JP2004/008492 patent/WO2004111037A1/ja not_active Application Discontinuation
- 2004-06-10 RU RU2006100301/04A patent/RU2006100301A/ru not_active Application Discontinuation
- 2004-06-10 CA CA002528929A patent/CA2528929A1/en not_active Abandoned
- 2004-06-10 TW TW093116667A patent/TW200508215A/zh unknown
-
2005
- 2005-12-01 IL IL172338A patent/IL172338A0/en unknown
- 2005-12-09 ZA ZA200510040A patent/ZA200510040B/en unknown
- 2005-12-12 US US11/301,296 patent/US20070049620A1/en not_active Abandoned
-
2006
- 2006-01-10 NO NO20060142A patent/NO20060142L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20060142L (no) | 2006-03-09 |
AU2004247560B2 (en) | 2007-11-29 |
AU2004247560A1 (en) | 2004-12-23 |
CN1863793A (zh) | 2006-11-15 |
ZA200510040B (en) | 2006-09-27 |
MXPA05013584A (es) | 2006-03-09 |
CA2528929A1 (en) | 2004-12-23 |
KR20060017865A (ko) | 2006-02-27 |
EP1632488A1 (en) | 2006-03-08 |
TW200508215A (en) | 2005-03-01 |
IL172338A0 (en) | 2009-02-11 |
RU2006100301A (ru) | 2006-07-10 |
WO2004111037A1 (ja) | 2004-12-23 |
US20070049620A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411221A (pt) | composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite | |
NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
BRPI0407810A (pt) | composto, composição farmacêutica, ativador da glicocinase, e, medicamento | |
BRPI0507984A (pt) | composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto | |
BR9908610A (pt) | Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos | |
KR910014350A (ko) | 3-아미노피페리딘 유도체 및 관련 질소 함유 헤테로사이클릭 화합물 | |
MX2009011755A (es) | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. | |
DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
BRPI0517621A (pt) | sais hidroxibenzoato de compostos de metanicotina | |
TNSN04203A1 (en) | Benzoxazinone-derived compounds, their preparation and use as medicaments | |
CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
UA99492C2 (ru) | Производные 1,3-дигидро-5-изобензофуранкарбонитрила и его фармацевтическая композиция для лечения преждевременной эякуляции | |
MXPA06000701A (es) | Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6. | |
MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
MX2020009287A (es) | Nuevo compuesto y composicion farmaceutica que lo comprende. | |
TW200730177A (en) | 4 anilino-3-quinolinecarbonitriles for the treatment of cancer | |
EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
MXPA05010165A (es) | Derivados de prolina biciclicos [c]-condensados y su uso para el tratamiento de estados artriticos. | |
MXPA05011168A (es) | Derivados de prolina biciclicos [b]-condensados y sus usos para tratar afecciones artriticas. | |
MY136965A (en) | 1,4-disubstituted piperidine compounds, their preparation and use as medicaments | |
MXPA05008833A (es) | D-homoestra-1,3,5(10)-trien-3-il-sulfamatos 2-sustituidos con actividad antitumoral. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |